Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2007

Open Access 01-12-2007 | Research article

Is there a uniform approach to the management of diffuse parenchymal lung disease (DPLD) in the UK? A national benchmarking exercise

Authors: Patricia Macedo, Robina K Coker, Martyn R Partridge

Published in: BMC Pulmonary Medicine | Issue 1/2007

Login to get access

Abstract

Background

Benchmarking is the comparison of a process to the work or results of others. We conducted a national benchmarking exercise to determine how UK pulmonologists manage common clinical scenarios in diffuse parenchymal lung disease (DPLD), and to determine current use and availability of investigative resources. We compared management decisions to existing international guidelines.

Methods

Consultant members of the British Thoracic Society were mailed a questionnaire seeking their views on the management of three common scenarios in DPLD. They were asked to choose from various management options for each case. Information was also obtained from the respondents on time served as a consultant, type of institution in which they worked and the availability of a local radiologist and histopathologist with an interest/expertise in thoracic medicine.

Results

370 out of 689 consultants replied (54% response rate). There were many differences in the approach to the management of all three cases. Given a scenario of relapsing pulmonary sarcoidosis in a lady with multiple co-morbidities, half of respondents would institute treatment with a variety of immunosuppressants while a half would simply observe. 42% would refer a 57-year old lady with new onset DPLD for a surgical lung biopsy, while a similar number would not. 80% would have referred her for transplantation, but a fifth would not. 50% of consultants from district general hospitals would have opted for a surgical biopsy compared to 24% from cardiothoracic centres: this may reflect greater availability of a radiologist with special interest in thoracic imaging in cardiothoracic centres, obviating the need for tissue diagnosis. Faced with an elderly male with high resolution CT thorax (HRCT) evidence of usual interstitial pneumonia (UIP), three quarters would observe, while a quarter would start immunosuppressants. 11% would refer for a surgical biopsy. 14% of UK pulmonologists responding to the survey revealed they had no access to a radiologist with an interest in thoracic radiology.

Conclusion

From our survey, it appears there is a lack of consensus in the management of DPLD. This may reflect lack of evidence, lack of resources or a failure to implement current guidelines.
Appendix
Available only for authorised users
Literature
2.
go back to reference Kiefe CI, Weissman NW, Allison JJ, Farmer R, Weaver M, Williams OD: Identifying achievable benchmarks of care: concepts and methodology. International Journal for Quality in Health Care. 1998, 10 (5): 443-447. 10.1093/intqhc/10.5.443.CrossRefPubMed Kiefe CI, Weissman NW, Allison JJ, Farmer R, Weaver M, Williams OD: Identifying achievable benchmarks of care: concepts and methodology. International Journal for Quality in Health Care. 1998, 10 (5): 443-447. 10.1093/intqhc/10.5.443.CrossRefPubMed
3.
go back to reference The Essence of Care – patient-focused benchmarks for clinical governance. NHS Modernisation Agency. 2003 The Essence of Care – patient-focused benchmarks for clinical governance. NHS Modernisation Agency. 2003
5.
go back to reference National Heart and Lung Institute. Respiratory Disease. Report on problems, research approaches, needs. 1972, Washington: DHEW (NIH), 73-432. National Heart and Lung Institute. Respiratory Disease. Report on problems, research approaches, needs. 1972, Washington: DHEW (NIH), 73-432.
6.
go back to reference Coultas DB, Zumwalt RE, Black WC: The epidemiology of interstitial lung disease. Am J Respir Crit Care Med. 1994, 150: 967-972.CrossRefPubMed Coultas DB, Zumwalt RE, Black WC: The epidemiology of interstitial lung disease. Am J Respir Crit Care Med. 1994, 150: 967-972.CrossRefPubMed
7.
go back to reference Demedts M, Wells AU, Antó JM, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato G, Polletti V, Verbeken EK, Thomeer MJ, Kokkarinen J, Delphin JC, Taylor AN: Interstitial lung disease: an epidemiological overview. European Respiratory Journal. 2001, 18 (suppl 32): 2s-16s. Demedts M, Wells AU, Antó JM, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato G, Polletti V, Verbeken EK, Thomeer MJ, Kokkarinen J, Delphin JC, Taylor AN: Interstitial lung disease: an epidemiological overview. European Respiratory Journal. 2001, 18 (suppl 32): 2s-16s.
8.
go back to reference Raghu G, Nyberg F, Morgan G: The epidemiology of interstitial lung disease and its association with lung cancer. British Journal of Cancer. 2004, 91 (suppl 2): S3-10. 10.1038/sj.bjc.6602061.CrossRefPubMedPubMedCentral Raghu G, Nyberg F, Morgan G: The epidemiology of interstitial lung disease and its association with lung cancer. British Journal of Cancer. 2004, 91 (suppl 2): S3-10. 10.1038/sj.bjc.6602061.CrossRefPubMedPubMedCentral
9.
go back to reference ATS/ERS International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002, 165: 277-304. ATS/ERS International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002, 165: 277-304.
10.
go back to reference British Thoracic Society: The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax. 1999, 54 (suppl 1): S1-30. British Thoracic Society: The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax. 1999, 54 (suppl 1): S1-30.
11.
go back to reference ATS statement on Sarcoidosis. Am J Respir Crit Care Med. 1999, 160: 736-755. ATS statement on Sarcoidosis. Am J Respir Crit Care Med. 1999, 160: 736-755.
12.
go back to reference Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Ekland A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP: ATS/ERS/WASOG Statement on Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999, 16: 149-173.PubMed Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Ekland A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP: ATS/ERS/WASOG Statement on Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999, 16: 149-173.PubMed
13.
go back to reference Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. International Consensus statement. Am J Respir Crit Care Med. 2000, 161: 646-664. Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. International Consensus statement. Am J Respir Crit Care Med. 2000, 161: 646-664.
14.
go back to reference Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U: Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. European Respiratory Journal. 1999, 14: 1117-1122. 10.1183/09031936.99.14511179.CrossRefPubMed Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U: Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. European Respiratory Journal. 1999, 14: 1117-1122. 10.1183/09031936.99.14511179.CrossRefPubMed
15.
go back to reference Lewis SJ, Ainslie GM, Bateman ED: Efficacy of azathioprine as second-line agent in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999, 16: 87-92.PubMed Lewis SJ, Ainslie GM, Bateman ED: Efficacy of azathioprine as second-line agent in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999, 16: 87-92.PubMed
16.
go back to reference Costabel U: Sarcoidosis: clinical update. European Respiratory Journal. 2001, 18 (suppl 32): 56s-68s. Costabel U: Sarcoidosis: clinical update. European Respiratory Journal. 2001, 18 (suppl 32): 56s-68s.
17.
go back to reference Sharma OP, Said A: Diagnosis, pathogenesis and treatment of sarcoidosis. Curr Opin Respir Med. 1995, 1: 392-400. Sharma OP, Said A: Diagnosis, pathogenesis and treatment of sarcoidosis. Curr Opin Respir Med. 1995, 1: 392-400.
18.
go back to reference Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD: The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease. A prospective study. Chest. 1999, 116: 1168-74. 10.1378/chest.116.5.1168.CrossRefPubMed Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD: The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease. A prospective study. Chest. 1999, 116: 1168-74. 10.1378/chest.116.5.1168.CrossRefPubMed
19.
go back to reference Hunninghake GW, Zimmerman MB, Schwartz DA, King TE, Lynch J, Hegele R, Waldron J, Colby T, Muller N, Lynch D, Galvin J, Gross B, Hogg J, Toews G, Helmers R, Cooper JA, Baughman R, Strange C, Millard M: Utility if a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001, 164: 193-96.CrossRefPubMed Hunninghake GW, Zimmerman MB, Schwartz DA, King TE, Lynch J, Hegele R, Waldron J, Colby T, Muller N, Lynch D, Galvin J, Gross B, Hogg J, Toews G, Helmers R, Cooper JA, Baughman R, Strange C, Millard M: Utility if a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001, 164: 193-96.CrossRefPubMed
20.
go back to reference du Bois RM: Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis. Clin Chest Med. 2006, 27: S17-S25. 10.1016/j.ccm.2005.08.001.CrossRefPubMed du Bois RM: Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis. Clin Chest Med. 2006, 27: S17-S25. 10.1016/j.ccm.2005.08.001.CrossRefPubMed
21.
go back to reference Diette GB, Scatarige JC, Haponik EF, Merriman B, Fisherman EK: Do high-resolution CT findings of usual interstitial pneumonitis obviate lung biopsy? Views of pulmonologists. Respiration. 2005, 72: 134-41. 10.1159/000084043.CrossRefPubMed Diette GB, Scatarige JC, Haponik EF, Merriman B, Fisherman EK: Do high-resolution CT findings of usual interstitial pneumonitis obviate lung biopsy? Views of pulmonologists. Respiration. 2005, 72: 134-41. 10.1159/000084043.CrossRefPubMed
22.
go back to reference Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A, Lynch JP, Martinez FJ: Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003, 58: 143-148. 10.1136/thorax.58.2.143.CrossRefPubMedPubMedCentral Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A, Lynch JP, Martinez FJ: Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003, 58: 143-148. 10.1136/thorax.58.2.143.CrossRefPubMedPubMedCentral
23.
go back to reference Flaherty KR, Travis WD, Colby WD, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, Martinez FJ: Histopathologic variability in usual and non-specific interstitial pneumonias. Am J Respir Crit Care Med. 2001, 164: 1722-1727.CrossRefPubMed Flaherty KR, Travis WD, Colby WD, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, Martinez FJ: Histopathologic variability in usual and non-specific interstitial pneumonias. Am J Respir Crit Care Med. 2001, 164: 1722-1727.CrossRefPubMed
24.
go back to reference Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR: High short-term mortality following lung biopsy for usual interstitial pneumonia. European Respiratory Journal. 2001, 17: 175-179. 10.1183/09031936.01.17201750.CrossRefPubMed Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR: High short-term mortality following lung biopsy for usual interstitial pneumonia. European Respiratory Journal. 2001, 17: 175-179. 10.1183/09031936.01.17201750.CrossRefPubMed
25.
go back to reference Sheldon TA, Colom N, Dawson D, Lankshear A, Lowson K, Watt I, West P, Wright D, Wright J: What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes and interviews. BMJ. 2004, 329: 999-1004. 10.1136/bmj.329.7473.999.CrossRefPubMedPubMedCentral Sheldon TA, Colom N, Dawson D, Lankshear A, Lowson K, Watt I, West P, Wright D, Wright J: What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes and interviews. BMJ. 2004, 329: 999-1004. 10.1136/bmj.329.7473.999.CrossRefPubMedPubMedCentral
26.
go back to reference Steinman MA, Fischer MA, Shlipak MG, Bosworth JB, Oddone EZ, Hoffman BB, Goldstein MK: Clinical awareness of adherence to hypertension guidelines. Am J Med. 2004, 117: 747-754. 10.1016/j.amjmed.2004.03.035.CrossRefPubMed Steinman MA, Fischer MA, Shlipak MG, Bosworth JB, Oddone EZ, Hoffman BB, Goldstein MK: Clinical awareness of adherence to hypertension guidelines. Am J Med. 2004, 117: 747-754. 10.1016/j.amjmed.2004.03.035.CrossRefPubMed
27.
go back to reference Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don't physicians follow clinical guidelines? A framework for improvement. JAMA. 1999, 282: 1458-1465. 10.1001/jama.282.15.1458.CrossRefPubMed Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don't physicians follow clinical guidelines? A framework for improvement. JAMA. 1999, 282: 1458-1465. 10.1001/jama.282.15.1458.CrossRefPubMed
28.
go back to reference Dennis SM, Edwards S, Partridge MR, Pinnock HJ, Qureshi SJ: The dissemination of the British Guideline on the management of asthma 2003. Respiratory Medicine. 2004, 98: 832-837. 10.1016/j.rmed.2004.02.018.CrossRefPubMed Dennis SM, Edwards S, Partridge MR, Pinnock HJ, Qureshi SJ: The dissemination of the British Guideline on the management of asthma 2003. Respiratory Medicine. 2004, 98: 832-837. 10.1016/j.rmed.2004.02.018.CrossRefPubMed
29.
go back to reference Partridge MR, Harrison BWD, Rudolf M, Bellamy D, Silverman M: The British Asthma Guidelines – Their production, dissemination and implementation. Respiratory Medicine. 1998, 92: 1046-1052. 10.1016/S0954-6111(98)90353-5.CrossRefPubMed Partridge MR, Harrison BWD, Rudolf M, Bellamy D, Silverman M: The British Asthma Guidelines – Their production, dissemination and implementation. Respiratory Medicine. 1998, 92: 1046-1052. 10.1016/S0954-6111(98)90353-5.CrossRefPubMed
30.
go back to reference Partridge MR: Translating research into practice: how are guidelines implemented?. European Respiratory Journal. 2003, 21 (suppl 39): 23s-29s. 10.1183/09031936.0.00054503.CrossRef Partridge MR: Translating research into practice: how are guidelines implemented?. European Respiratory Journal. 2003, 21 (suppl 39): 23s-29s. 10.1183/09031936.0.00054503.CrossRef
31.
go back to reference Paramothayan NS, Lasserson TJ, Jones PW: Corticosteroids for pulmonary sarcoidosis (Cochrane Review). The Cochrane Library. 2005, 2 Paramothayan NS, Lasserson TJ, Jones PW: Corticosteroids for pulmonary sarcoidosis (Cochrane Review). The Cochrane Library. 2005, 2
32.
go back to reference Richeldi L, Davies HR, Ferrara G, Franco F: Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003, CD002880-3 Richeldi L, Davies HR, Ferrara G, Franco F: Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003, CD002880-3
34.
go back to reference Nathan S: Assessing the role of the International Consensus Guidelines. Chest. 2005, 128: 533S-539S. 10.1378/chest.128.5_suppl_1.533S.CrossRefPubMed Nathan S: Assessing the role of the International Consensus Guidelines. Chest. 2005, 128: 533S-539S. 10.1378/chest.128.5_suppl_1.533S.CrossRefPubMed
35.
go back to reference Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR, Hasleton PS, Kerr KM, Ibrahim NB, Stewart S, Wallace WA, Wells AU: Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax. 2004, 59: 500-505. 10.1136/thx.2003.011734.CrossRefPubMedPubMedCentral Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR, Hasleton PS, Kerr KM, Ibrahim NB, Stewart S, Wallace WA, Wells AU: Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax. 2004, 59: 500-505. 10.1136/thx.2003.011734.CrossRefPubMedPubMedCentral
36.
go back to reference Aziz ZA, Wells AU, Hansell DM, Bain GA, Copley SJ, Desai SR, Ellis SM, Gleeson FV, Grubnic S, Nicholson AG, Padley SP, Pointon KS, Reynolds JH, Robertson RJ, Rubens MB: HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax. 2004, 59: 506-511. 10.1136/thx.2003.020396.CrossRefPubMedPubMedCentral Aziz ZA, Wells AU, Hansell DM, Bain GA, Copley SJ, Desai SR, Ellis SM, Gleeson FV, Grubnic S, Nicholson AG, Padley SP, Pointon KS, Reynolds JH, Robertson RJ, Rubens MB: HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax. 2004, 59: 506-511. 10.1136/thx.2003.020396.CrossRefPubMedPubMedCentral
37.
go back to reference Lettieri CJ, Veerappan GR, Parker JM, Franks TJ, Hayden D, Travis WD, Shorr AF: Discordance between general and pulmonary pathologist in the diagnosis of interstitial lung disease. Respiratory Medicine. 2005, 99: 1425-1430. 10.1016/j.rmed.2005.03.008.CrossRefPubMed Lettieri CJ, Veerappan GR, Parker JM, Franks TJ, Hayden D, Travis WD, Shorr AF: Discordance between general and pulmonary pathologist in the diagnosis of interstitial lung disease. Respiratory Medicine. 2005, 99: 1425-1430. 10.1016/j.rmed.2005.03.008.CrossRefPubMed
Metadata
Title
Is there a uniform approach to the management of diffuse parenchymal lung disease (DPLD) in the UK? A national benchmarking exercise
Authors
Patricia Macedo
Robina K Coker
Martyn R Partridge
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2007
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-7-3

Other articles of this Issue 1/2007

BMC Pulmonary Medicine 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine